Physician profile

Tiffaney White

Family · Bowie, MD

NPI 1043941743

$1,143.33

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,062.83

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Sun Pharmaceutical Industries INC. $220.56 2024
Neurocrine Biosciences, INC. $217.63 2024 Ingrezza
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $134.27 2024 Caplyta
E.R. Squibb & Sons, L.L.C. $120.39 2024 Zeposia
Biogen, INC. $112.55 2023
Abbvie INC. $108.30 2024
Boston Scientific Corporation $98.55 2024 Wavewriter Alpha Prime 16
Janssen Scientific Affairs, LLC $80.50 2022
Neurelis, INC. $50.58 2024 Valtoco

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Tiffaney White

$1,143.33

in general payments reported 2019-2025

Years
2022-2024
Top company
Sun Pharmaceutical Industries INC.

https://glasscript.com/doctor/11358221/tiffaney-white

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.